Dramatic increase in use of generic drugs in Japan confirmed

15 October 2013
drugs_pills_tablets_big

A subcommittee of Japan’s Central Social Insurance Medical Council (CSIMC) looked at the effect of April 2012 revision to the Medical Fee System, resulting in evidence of greater use of generic medicines, reports The Pharma Letter’s local analyst.

The subcommittee verified that ratio of generic drugs of all the dispensed medicines increased from 24% in 2011 to nearly 30% by August 2012. The gain of 6 percentage points in volume share was a result of the government’s policy to promote generics, concluded the CSIMC.

As of April last year, the government changed the prescription format so as to increase the burden for medical doctors who wanted to fend off generics. After the change, doctors now have to mark with their signature check boxes of each prescribed medicines when they want to refuse generic substitution by pharmacies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics